Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...
The major COVID variants we've seen so far and which one to look out for right now
Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...
Cautious Outlook on Moderna: Declining Vaccine Demand and Strategic Challenges Prompt Sell Rating
Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...
Jury awards $12M to woman fired for refusing COVID vax. Hundreds of similar suits pending.
The Wyandotte woman had worked at Blue Cross for 32 years and was denied a religious accommodation to the insurer's vaccine ...
The Canadian Press on MSN2d
Health Canada approves Moderna's mRNA RSV vaccine, company says
Health Canada has approved Moderna's mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older — ...
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
2 Biotech Stocks You Can Buy Hand Over Fist This Month
Both stocks have made significant breakthroughs. Among the qualities a biotech company needs to be successful, being innovative is one of the most important. It's easy to understand why. Although ...
Canada approves Moderna's RSV vaccine for adults aged 60 and older
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Why You Should Get Your Vaccines Before the Holiday Rush
Health professionals recommend vaccines before traveling to celebrate the holidays with family. If you missed the early fall ...
Moderna’s Mixed Performance: Strong Spikevax Sales Drive Q3 Success Amid mRESVIA Uncertainties, Resulting in Hold Rating
Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...
Moderna sales get lift from early nod for newest COVID shot
The Cambridge-based company’s latest COVID shot was approved three weeks earlier than last year, according to a statement ...
Pfizer, GSK, Moderna struggle in a shrinking RSV vaccine market
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...